Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INBX

Inhibrx Inc

May 10 • 04:00PM ET

34.29

Dollar change -0.40
Percentage change -1.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO LABU VTWO SCHA IWN IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.35	Insider Own	24.89%	Shs Outstand	47.37M	Perf Week	0.41%
Market Cap	1.79B	Forward P/E	-	EPS next Y	-4.30	Insider Trans	0.00%	Shs Float	39.26M	Perf Month	-2.08%
Income	-271.15M	PEG	-	EPS next Q	-1.23	Inst Own	75.04%	Short Float	5.59%	Perf Quarter	-8.32%
Sales	1.78M	P/S	1007.12	EPS this Y	4.39%	Inst Trans	7.25%	Short Ratio	4.72	Perf Half Y	79.72%
Book/sh	0.23	P/B	145.94	EPS next Y	12.16%	ROA	-100.00%	Short Interest	2.19M	Perf Year	32.60%
Cash/sh	4.83	P/C	7.10	EPS next 5Y	-	ROE	-2031.05%	52W Range	14.31 - 39.79	Perf YTD	-9.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.13%	ROI	-125.13%	52W High	-13.82%	Beta	2.85
Dividend TTM	-	Quick Ratio	3.82	Sales past 5Y	-16.05%	Gross Margin	5.05%	52W Low	139.71%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	3.82	EPS Y/Y TTM	-35.87%	Oper. Margin	-13980.93%	RSI (14)	45.24	Volatility	1.26% 1.24%
Employees	172	Debt/Eq	18.23	Sales Y/Y TTM	39.30%	Profit Margin	-15207.80%	Recom	3.00	Target Price	35.00
Option/Short	Yes / Yes	LT Debt/Eq	17.73	EPS Q/Q	-28.52%	Payout	-	Rel Volume	1.05	Prev Close	34.69
Sales Surprise	3168.00%	EPS Surprise	-66.88%	Sales Q/Q	-100.00%	Earnings	Feb 28 BMO	Avg Volume	465.12K	Price	34.29
SMA20	-0.17%	SMA50	-1.63%	SMA200	24.84%	Trades		Volume	486,933	Change	-1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-23-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Mar-16-22	Initiated	SMBC Nikko	Outperform	$40
Sep-21-21	Initiated	JMP Securities	Mkt Outperform	$46
Apr-26-21	Resumed	Credit Suisse	Outperform	$44
Sep-14-20	Initiated	Evercore ISI	Outperform	$30
Sep-14-20	Initiated	Credit Suisse	Outperform	$26

May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)
May-08-24 04:37PM	Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger (PR Newswire)
Feb-28-24 10:25AM	Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.47%
09:15AM	Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results (PR Newswire)
Jan-29-24 11:53PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL (PR Newswire)
12:12PM	Loading…
Jan-26-24 12:12PM	Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm (PR Newswire)
Jan-24-24 09:46AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, MDC, ANSS, HMST (GlobeNewswire)
05:58AM	Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-23-24 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal) +8.91%
04:42PM	These Stocks Moved the Most Today: United, 3M, Verizon, Plug Power, Johnson & Johnson, GE, and More (Barrons.com)
04:02PM	Inhibrx Soared 176% Over Two Months Now, Sanofi Is Buying It (Investor's Business Daily)
02:45PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, SP, WAVD, CATC (PR Newswire)
02:30PM	Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi (Zacks)
01:23PM	These Stocks Are Moving the Most Today: United, 3M, Verizon, Plug Power, Johnson & Johnson, GE, and More (Barrons.com)
11:25AM	Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline (Investopedia)
09:40AM	Loading…
09:40AM	Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx (Investor's Business Daily)
06:02AM	Sanofi to buy Inhibrx in deal worth up to $2.2B (BioPharma Dive)
05:39AM	Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion (The Wall Street Journal)
05:27AM	Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs (FierceBiotech.com)
01:32AM	France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal (Reuters)
01:29AM	UPDATE 3-France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal (Reuters)
01:12AM	France's Sanofi to buy U.S. drugs project INBRX-101 for around $2.2 bln (Reuters)
01:00AM	Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B (PR Newswire)
Nov-09-23 04:00PM	Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
Nov-02-23 09:15AM	Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma (PR Newswire)
Oct-18-23 04:00PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Sep-19-23 04:00PM	Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada (PR Newswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
Aug-29-23 09:00AM	Inhibrx Announces $200 Million Private Placement Financing (PR Newswire) +13.33%
Aug-07-23 04:00PM	Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire) -6.21%
09:00AM	Loading…
May-30-23 09:00AM	Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
May-08-23 06:05PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
May-03-23 09:58PM	Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength? (Zacks) +9.89%
02:18PM	Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating (Investor's Business Daily)
Apr-26-23 09:00AM	Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials (PR Newswire)
Mar-23-23 07:25AM	The past year for Inhibrx (NASDAQ:INBX) investors has not been profitable (Simply Wall St.)
Mar-06-23 05:35PM	Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results (PR Newswire)
Jan-30-23 07:33AM	Should You Hold Inhibrx (INBX)? (Insider Monkey) -7.41%
Jan-04-23 09:00AM	NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates (PR Newswire)
Nov-18-22 04:05PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
10:16AM	Inhibrx (INBX) Down on Updated Data From Bone Cancer Study (Zacks)
Nov-16-22 10:42AM	Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate (Benzinga)
09:00AM	Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
Nov-09-22 06:08AM	Inhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-07-22 05:55PM	Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.04%
04:05PM	Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
Oct-20-22 04:05PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-13-22 06:56AM	Investors in Inhibrx (NASDAQ:INBX) have unfortunately lost 18% over the last year (Simply Wall St.) +6.46%
Oct-04-22 09:28AM	Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge (Benzinga) +47.47%
08:00AM	Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study (PR Newswire)
Oct-03-22 04:30PM	Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire) +12.42%
Aug-15-22 04:05PM	European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
Aug-08-22 07:25PM	Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.27%
05:19PM	Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
Jun-30-22 09:00AM	Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance (PR Newswire) -5.34%
May-19-22 04:05PM	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting (PR Newswire) -5.08%
May-16-22 12:32PM	Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder (Benzinga) -18.95%
09:00AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
May-09-22 06:35PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.23%
05:25PM	Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
May-05-22 05:15PM	KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.76%
06:18AM	The 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25% (Simply Wall St.)
May-03-22 06:32AM	Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock? (Zacks)
Apr-25-22 09:00AM	Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 (PR Newswire)
Apr-05-22 04:30PM	Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting (PR Newswire) -5.50%
Mar-24-22 04:05PM	Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting (PR Newswire)
Mar-03-22 09:15AM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
Feb-28-22 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
Feb-22-22 09:00AM	Inhibrx Announces Amended Loan Agreement with Oxford (PR Newswire)
Jan-05-22 07:46AM	Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors (Benzinga) -5.83%
Jan-04-22 04:05PM	Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data (PR Newswire) -8.62%
Dec-20-21 08:50AM	Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price Strength (Zacks)
Dec-01-21 04:05PM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma (PR Newswire)
Nov-25-21 09:08AM	Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval (Zacks)
Nov-24-21 10:31AM	Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension (Zacks) +5.48%
Nov-23-21 10:00AM	Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should Know (Zacks)
Nov-10-21 07:47AM	Inhibrx (NASDAQ:INBX) pulls back 3.4% this week, but still delivers shareholders impressive 139% return over 1 year (Simply Wall St.)
Nov-09-21 06:45PM	Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
Nov-05-21 03:00PM	Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-21 08:00AM	Inhibrx Announces Presentations at SITC 2021 (PR Newswire)
Nov-01-21 05:51PM	Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences (PR Newswire) +14.51%
Oct-28-21 08:30AM	Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-12-21 12:22PM	30 Stocks Moving In Tuesday's Mid-Day Session (Benzinga) +21.98%
12:11PM	Here's Why Inhibrx Stock Is on the Move Today (Motley Fool)
07:30AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
Oct-11-21 04:05PM	Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
Sep-13-21 04:30PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
Aug-12-21 01:37AM	The Inhibrx, Inc. (NASDAQ:INBX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.) -6.10%
Aug-09-21 04:38PM	Inhibrx Reports Second Quarter 2021 Financial Results (PR Newswire)
Jun-22-21 06:49AM	Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford (Benzinga)
Jun-21-21 04:05PM	Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford (PR Newswire)
May-17-21 04:05PM	Inhibrx Announces Participation in Upcoming Investor Conferences (PR Newswire)
May-13-21 04:10PM	Inhibrx Reports First Quarter 2021 Financial Results (PR Newswire)
Mar-14-21 03:21AM	Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish (SmarterAnalyst)
Mar-12-21 09:00AM	Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist (PR Newswire) -6.37%
Feb-01-21 05:42PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire) +7.32%

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm's pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Aug 28 '23	Buy	19.35	511,627	9,899,982	511,627	Aug 30 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Inc

Upgrade your FINVIZ experience